SAN FRANCISCO, CA--(Marketwired - January 23, 2017) - The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11.

Included in this article is: Sorrento Therapeutics Inc. (NASDAQ: SRNE)

Raghuram "Ram" Selvaraju of Rodman & Renshaw placed Sorrento Therapeutics on the Watchlist. He noted that Sorrento Therapeutics Inc. "is doing some of the most exciting work we see in the antibody space, particularly with its collaboration with the City of Hope." Sorrento is developing candidates "that can go inside the cell and chase the target there wherever it may hide," which has "significant ramifications for overcoming cancer cell resistance to some of the most widely used anti-cancer targeted therapy monoclonal antibodies," Selvaraju said. Sorrento is also in the immunotherapy space, "primarily focused on the development of an allogeneic solution to a cell-based immunotherapy problem." The company, he believes, "is going to provide a rich vein of value-driving catalysts in the year ahead."

Continue reading this article: 2017 Small-Cap Biotech Watchlist: Takeaways for Investors

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURE:

The following companies paid Streetwise Reports to issues a press release on their behalf relating to this article: Sorrento Therapeutics Inc. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

Please see the end of the article for the complete disclosure: 2017 Small-Cap Biotech Watchlist: Takeaways for Investors